Parkinson's Disease

The emergence of COVID-19-induced parkinsonism 2:48
The emergence of COVID-19-induced parkinsonism
Angelo Antonini • 29 Mar 2022
Increasing mobility in patients with Parkinson’s disease during COVID-19 2:58
Increasing mobility in patients with Parkinson’s disease during COVID-19
Angelo Antonini • 29 Mar 2022
The role of phosphoinositides in Parkinson’s disease pathology 1:13
The role of phosphoinositides in Parkinson’s disease pathology
Ronit Sharon • 18 Mar 2022
The impact of extreme stress on the brain: Holocaust survivors study 3:08
The impact of extreme stress on the brain: Holocaust survivors study
Ivan Rektor • 17 Mar 2022
Insights into Parkinson’s disease pathology: α-syn & phosphoinositides 2:50
Insights into Parkinson’s disease pathology: α-syn & phosphoinositides
Ronit Sharon • 18 Mar 2022
Is α-synuclein a useful therapeutic target in Parkinson’s disease? 4:31
Is α-synuclein a useful therapeutic target in Parkinson’s disease?
Amos Korczyn • 7 Mar 2022
Managing Parkinson’s Disease with probiotics 3:27
Managing Parkinson’s Disease with probiotics
Valentina Leta • 24 Mar 2022
Establishing the link between the Parkinson’s Disease and gut microbiota 4:06
Establishing the link between the Parkinson’s Disease and gut microbiota
Valentina Leta • 24 Mar 2022
Evaluating probiotics as a treatment for Parkinson’s Disease 1:29
Evaluating probiotics as a treatment for Parkinson’s Disease
Valentina Leta • 24 Mar 2022
Brain region-specific changes in α-synuclein conformations in Parkinson’s disease 1:22
Brain region-specific changes in α-synuclein conformations in Parkinson’s disease
Tim Bartels • 17 Mar 2022
AD/PD highlights: α-synuclein PET tracer 1:32
AD/PD highlights: α-synuclein PET tracer
Tiago Outeiro • 18 Mar 2022
Hippocampus atrophy and white matter lesions in PD & AD 2:15
Hippocampus atrophy and white matter lesions in PD & AD
Ivan Rektor • 17 Apr 2022
Hippocampal volume changes in Parkinson’s disease 2:05
Hippocampal volume changes in Parkinson’s disease
Ivan Rektor • 17 Mar 2022
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease 1:21
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease
Tim Bartels • 17 Mar 2022
Treating central autonomic disorders 1:52
Treating central autonomic disorders
Elizabeth Coon • 1 Apr 2022
In vivo interactions between Nedd4 ubiquitin ligases and α-synuclein in Parkinson’s disease models 3:52
In vivo interactions between Nedd4 ubiquitin ligases and α-synuclein in Parkinson’s disease models
James Conway • 11 Mar 2022
The content of VJNeurology is intended for healthcare professionals